Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA guidance on drug names expected in "near future," agency's Woodcock says.

This article was originally published in The Tan Sheet

Executive Summary

FDA GUIDANCE ON PHARMACEUTICAL DRUG NAMES EXPECTED IN "NEAR FUTURE," Center for Drug Evaluation & Research Director Janet Woodcock, MD, said at FDA's Minimizing Medical Product Errors conference in Bethesda, Md. Jan. 8. The guidance will outline principles for the pharmaceutical industry "when selecting proprietary names," Woodcock said, because "as more and more drugs get on the market, it has become an increasing problem in developing proprietary names that cannot, either written or verbally, be confused with another drug."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087939

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel